
Amy P. Abernethy
Oncologist
3
APPEARANCES
3
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Nov 14, 2026
Announcement | David MacGregor | Ashburton
5:42
6:06

Brendan AbernethyGUEST
But maybe I'll just, in that, I'll hand it to Amy to your journey, sweetie.

Amy AbernethyGUEST
And even, you know, for me, like when Brendan was first kind of starting to say, I feel like the Lord might be saying this.
20 MINS LATER
Beyond the Gold Standard: Why Real-World Data Belongs in Medicine
11:19
11:27
11:45
12:00
12:15
12:39

Scott SigmanHOST
How does this real-world data, we've got it now, we've got this information, how is that going to help to change what we do?

Amy AbernethyGUEST
As data sets now come together, so let's, for example, use a data set around people with non-small cell lung cancer, some of whom have received immunotherapy and some of whom received standard chemotherapy, and you want to understand what is the potential incremental benefit of immunotherapy.

Amy AbernethyGUEST
So as these data sets first are de-identified and prepared for analysis, It allows us then to analyze and ask a question like immunotherapy as compared to standard chemotherapy, but also drill in further.

Amy AbernethyGUEST
So for example, for which patients does there seem to be more of an improvement with immunotherapy over others? Maybe that's by a genetic kind of element that seems to lead to a potential proclivity towards one treatment working better than another.

Amy AbernethyGUEST
Also, for example, how might this data set actually inform people who historically would never have made it into clinical trials? So for example, people who are represented in the data who have some evidence of kidney failure or liver failure, who never would have been involved in clinical trials, but now oftentimes are receiving care in routine care, and their information can also contribute to the future.

Amy AbernethyGUEST
But we're moving quickly to a place where the analytic framework, both the analytic capabilities, including sort of modern scientific capabilities like causal inference and modern tools such as artificial intelligence, coupled with much more facile data preparation capabilities have gotten us to this place where we actually can start to not just do this as bulk analysis that takes six or 18 months to do each of these analyses, but we can actually do it much faster and start to have much more in real time.
8 MINS LATER
U.S.-China Clinical Research: Speed, Evidence, and Global Competitiveness
2:01
2:14
2:22
2:33
2:48
3:02
10:57

Ruby WangHOST
So can you start off by describing to us why are clinical trials seemingly faster in China? What is the source of all of this efficiency, and where are the differences most noticeable between China and the US?

Amy AbernethyGUEST
It'll be helpful to go back to h- how did we get to the place where the US biomedical leadership emerged.

Amy AbernethyGUEST
But first, let's talk about China and the efficiency in front of us, and how did China become a locus of clinical development.

Amy AbernethyGUEST
It wasn't an organic drift, and the pivot traces back to a single policy, a state council policy in twenty fifteen called Opinions on Reform of the Review and Approval Process for Drugs and Medical Devices.

Amy AbernethyGUEST
That redesigned really every stage of the development li- lifecycle, and we describe this in some detail in a Nature Medicine commentary published in June of this year.

Amy AbernethyGUEST
That ten-year plan that we have seen now get put in motion, and its output has been a key driver behind the efficiency that you describe.
8 MINS LATER

Ruby WangHOST
Is that okay? Does that produce reliable results? How can we balance speed with safety? And it would be great if you could bring in all of your expertise, including at the FDA, to compare which parts of the US system might accelerate or slow down trials in a way that provides additional benefit or maybe less so.